Evidence map›Paper›PMID 42653230›Full record

ArticleInternational journal of molecular sciences2026

5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

Natalia V Mitiushkina, Elena V Preobrazhenskaya, Aleksandr A Romanko, Anna D Shestakova, Rimma S Belova, Tatiana Y Velyukhova, Yana I Tretyakova, Natalia A Firsova, Ekaterina A Nalivalkina, Vladislav I Tiurin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natalia V MitiushkinaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0000-0002-0179-3191
Elena V PreobrazhenskayaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0000-0001-7800-013X
Aleksandr A RomankoDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0000-0002-6549-8378
Anna D ShestakovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.
Rimma S BelovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.
Tatiana Y VelyukhovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0009-0006-8243-9800
Yana I TretyakovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.
Natalia A FirsovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.
Ekaterina A NalivalkinaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0009-0000-1955-1433
Vladislav I TiurinDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0000-0002-0157-5952
Evgeny N ImyanitovDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg 197758, Russia.ORCID 0000-0003-4529-7891

Funding

Russian Science Foundation 25-15-00577
6 · The paper itself

Abstract

Next-generation sequencing (NGS) is currently regarded as a preferable method for detection of actionable alterations in non-small cell lung carcinomas (NSCLCs). RNA-based NGS is particularly efficient in detection of gene fusions and allows for mRNA expression analysis of relevant genes. This study describes a novel library preparation pipeline for targeted RNA sequencing, which is based on the 5' rapid amplification of the cDNA ends (5' RACE) and anchored multiplex PCR. The NGS panel was designed for the analysis of 15 genes relevant to NSCLC therapeutic decisions (

Indexed as

Carcinoma, Non-Small-Cell LungDNA, ComplementaryHigh-Throughput Nucleotide SequencingLung NeoplasmsSequence Analysis, RNAAdultAgedFemaleHumansMaleMiddle AgedMutationDNA, Complementary5′ RACEfusionNSCLCrearrangementtargeted RNA sequencingtargeted therapy

Identifiers

PMID42653230
PMCPMC13513894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.